troleandomycin has been researched along with nevirapine in 3 studies
Studies (troleandomycin) | Trials (troleandomycin) | Recent Studies (post-2010) (troleandomycin) | Studies (nevirapine) | Trials (nevirapine) | Recent Studies (post-2010) (nevirapine) |
---|---|---|---|---|---|
569 | 26 | 23 | 3,212 | 509 | 1,108 |
Protein | Taxonomy | troleandomycin (IC50) | nevirapine (IC50) |
---|---|---|---|
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Reverse transcriptase/ribonuclease H | Human immunodeficiency virus 1 | 1.165 | |
Prothrombin | Bos taurus (cattle) | 1.15 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | 1.4504 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 2.05 | |
Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 1.4353 | |
Imidazoleglycerol-phosphate dehydratase | Saccharomyces cerevisiae S288C | 1.7 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.181 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.181 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.69 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.7 | |
Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 5.75 | |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.18 | |
Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.071 | |
Protease | Human immunodeficiency virus 1 | 0.101 | |
Reverse transcriptase | Human immunodeficiency virus 1 | 3.995 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Erickson, DA; Keirns, JJ; Levy, RH; Mather, G; Trager, WF | 1 |
3 other study(ies) available for troleandomycin and nevirapine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.
Topics: Antibodies; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Drug Interactions; HIV Reverse Transcriptase; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Nevirapine; Phenotype; Recombinant Proteins; Reverse Transcriptase Inhibitors; Troleandomycin | 1999 |